Shares rock­et up as Nabri­va Ther­a­peu­tics touts a PhI­II win for an­tibi­ot­ic

Two weeks af­ter its chief med­ical of­fi­cer re­signed, spark­ing jit­ters among the more hope­ful an­a­lysts fol­low­ing the com­pa­ny, Nabri­va Ther­a­peu­tics $NBRV an­nounced that its key …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER